This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.
The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
by Zacks Equity Research
The Medicines Company (MDCO) reports wider-than-expected loss with revenues missing estimates. The top line also decreases year over year due to low Angiomax sales.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
by Zacks Equity Research
The first half has been pretty strong for companies in the space.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
by Zacks Equity Research
On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Are Medicines Company's Key Drugs Set for Growth in 2017?
by Zacks Equity Research
On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).
Alnylam Commences Phase III Study for Hemophilia Candidate
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
by Zacks Equity Research
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.
Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).
Regeneron Presents Positive Phase II Data on HoFH Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
by Zacks Equity Research
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session.
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.
The Medicines Company (MDCO) Q1 Loss Wider Than Expected
by Zacks Equity Research
The Medicines Company (MDCO) reported loss $1.44 per share, wider than the Zacks Consensus Estimate of a loss of $1.13.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.
Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's LDL-Lowering Drug Positive in Phase II Study
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.